Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. Atara ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value ...

U.S. FDA issues clinical hold on EBVALLO™ (tabelecleucel) and ATA3219 studies linked to EBVALLO Complete Response Letter (CRL) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

A couple of months after Thousand Oaks-based Atara Biotherapeutics announced it would be laying off roughly 80 employees, the company confirmed nearly half of those jobs are coming from its Ventura ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy ...

Eric J. Hyllengren, vicepresidente ejecutivo, director financiero y director de operaciones de Atara Biotherapeutics, Inc. (NASDAQ:ATRA), vendió recientemente 1.211 acciones ordinarias de la empresa.

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

Atara Biotherapeutics Inc ( (ATRA)) has released its Q4 earnings. Here is a breakdown of the information Atara Biotherapeutics Inc presented to its investors. See what stocks are receiving Strong ...

The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world. Following a positive recommendation ...